Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?
Crossref DOI link: https://doi.org/10.1038/bmt.2017.28
Published Online: 2017-03-13
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lee, H
Duggan, P
Neri, P
Tay, J
Bahlis, N J
Jimenez-Zepeda, V H
Text and Data Mining valid from 2017-03-13
Version of Record valid from 2017-03-13
Article History
First Online: 13 March 2017
Competing interests
: The authors declare no conflict of interest.